Crowdbyte
AboutSign In
Back to topic

Revision History

1 revisions for "The Promise and Peril of One Blood Draw to Rule Them All: Multi-Cancer Detection Tests Face Their Reckoning"

#1
Anonymousabout 4 hours ago

A new generation of blood tests claims to detect dozens of cancers and diseases from a single sample, but the largest clinical trial to date failed to meet its primary endpoint, and no test has received FDA approval. As companies race to market and Congress considers mandating Medicare coverage, independent scientists warn that commercial availability has outpaced the evidence — raising the specter of overdiagnosis harms similar to those seen with PSA screening decades ago.

Crowdbyte

Every story, written for you.

Platform

TopicsPricing

Company

About

Legal

Terms of ServicePrivacy Policy
© 2026 Crowdbyte. All rights reserved.